All In Biotech

Drug Trial Radar · NCT01947907

Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)

A Multicenter, Phase 2, Randomized, Open Label, Active-controlled, Parallel-group Study Investigating the Safety, Tolerability, and Efficacy of Different Dose Levels of ACP-001 Administered Once Weekly Versus Standard Daily rhGH Replacement Therapy in Pre-pubertal Children With Growth Hormone Deficiency (GHD)

Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

53

Actual

Start

Jul 2013

Primary completion

Jul 2015

Study completion Sep 2015

Sponsor

Lead sponsor
Ascendis Pharma A/SIndustry
Sponsor type
Industry
First posted
Sep 23, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 3 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A six month study of ACP-001, a long-acting growth hormone product, versus standard human growth hormone therapy. ACP-001 will be given once-a-week, standard human growth hormone (hGH) will be given on a daily basis. The primary aim is to demonstrate safety, pharmacokinetics and pharmacodynamics over a period of six months. A secondary objective is the comparison of height velocity (HV) of the ACP-001 treated groups to the daily hGH treatment group.

Conditions

  • Growth Hormone Deficiency (GHD)

Interventions

  • ACP-001Drug

    Once weekly subcutaneous injection

  • Human Growth HormoneDrug

    Once daily subcutaneous injection of human Growth Hormone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Anti-hGH Binding Antibody FormationTime frame: Visit 2 - Visit 5
  2. Incidence of Anti-hGH Neutralizing Antibody FormationTime frame: Visit 2 - Visit 5
  3. Number of Subjects Reporting Local Tolerability Events (Assessed by the Patient and Investigator)Time frame: Start of study treatment through Visit 5 (Week 27)
  4. Cmax of hGHTime frame: 0 hours to 168 hours at Visit 3 (Week 13)
  5. AUC0-168h of hGHTime frame: 0 hours to 168 hours at Visit 3 (Week 13)
  6. E-Trough of IGF-1Time frame: 0 hours to 168 hours at Visit 3 (Week 13)
  7. Emax of IGF-1Time frame: 0 hours to 168 hours at Visit 3 (Week 13)
  8. AUEC0-168h of IGF-1Time frame: 0 hours to 168 hours at Visit 3 (Week 13)

Locations

36 sites in 14 countries. Site status is shown where the registry gives one.

  • 2nd Children City Clinic

    Minsk, Belarus

  • University Multiprofile Hospital for Active Treatment (UMHAT) "Sv. Marina"

    Varna, Bulgaria

  • Masaryk´s Hospital

    Ústí nad Labem, Czechia

  • El Shatby University Hospital

    Alexandria, Egypt

  • Ain Shams University Hospital

    Cairo, Egypt

  • Cairo University Hospital

    Cairo, Egypt

  • El Mansoura University Hospital

    El Mansoura, Egypt

  • Hôpital des enfants Pellegrin

    Bordeaux, France

  • Hôpital Jeanne de Flandre

    Lille, France

  • Hôpital Femme-Mère-Enfant

    Lyon, France

  • University Hospital Leipzig

    Leipzig, Germany

  • University Children's Hospital Magdeburg

    Magdeburg, Germany

  • Children's Hospital of Athens "P. A. Kyriakou"

    Athens, Greece

  • Buda Children's Hospital

    Budapest, Hungary

  • Heim Pal Children's Hospital

    Budapest, Hungary

  • University of Pecs

    Pécs, Hungary

  • University of Szeged

    Szeged, Hungary

  • University Medical Hospital

    Katowice, Poland

  • Medical University of Lublin

    Lublin, Poland

  • Regional Hospital N°2 Rzeszow

    Rzeszów, Poland

  • Children's Memorial Health Institute Warsaw

    Warsaw, Poland

  • Emergency Clinical Hospital Cluj-Napoca

    Cluj-Napoca, Romania

  • St. Spiridon County Clinic Emergency Hospital

    Iași, Romania

  • Louis Turcanu Emergency Hospital for Children Timisoara

    Timișoara, Romania

  • Federal State Budgetary Institution

    Moscow, Russia

  • St. Petersburg State Pediatric Medical Academy

    Saint Petersburg, Russia

  • Samara State Medical University

    Samara, Russia

  • Bashkir State Medical University

    Ufa, Russia

  • Children's University Hospital

    Ljubljana, Slovenia

  • Ankara University School of Medicine

    Ankara, Turkey (Türkiye)

  • Ege Üniversity

    Izmir, Turkey (Türkiye)

  • Donetsk Regional Children Clinical Hospital

    Donetsk, Ukraine

  • Kharkiv National Medical University

    Kharkiv, Ukraine

  • Institute of Endocrinology and Metabolism

    Kiev, Ukraine

  • Ukrainian Children Specialized Clinical Hospital

    Kiev, Ukraine

  • Odessa National Medical University

    Odesa, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.